Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
Open Access
- 6 May 2021
- journal article
- research article
- Published by Elsevier BV in European Urology Open Science
- Vol. 28, 52-61
- https://doi.org/10.1016/j.euros.2021.04.005
Abstract
No abstract availableFunding Information
- Pantarhei Bioscience BV
This publication has 33 references indexed in Scilit:
- Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)The Lancet Oncology, 2013
- PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy EraEndocrine, 2013
- Blockade of testicular and adrenal androgens in prostate cancer treatmentNature Reviews Urology, 2011
- Estetrol review: profile and potential clinical applicationsClimacteric, 2008
- Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis modelClimacteric, 2008
- The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate CancerClinical Cancer Research, 2004
- Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushesEmergencias, 2004
- Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapyInternational Journal of Urology, 2004
- Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the ProstateJournal of Urology, 2002
- Estrogen therapy for prostate carcinomaJAMA, 1996